RecruitingPhase 2NCT07157007

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19

Sponsor

Traws Pharma, Inc.

Enrollment

90 participants

Start Date

Sep 16, 2025

Study Type

INTERVENTIONAL

Conditions

COVID-19

Summary

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Paxlovid, a drug called Ratutrelvir (83-0060), and others for people with covid-19. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRatutrelvir (83-0060) non-randomised

83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)

DRUGPaxlovid

Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor)

DRUGRatutrelvir (83-0060)

83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)

Locations(15)

Novatrial

Charlestown, New South Wales, Australia

Key Health

Sydney, New South Wales, Australia

Momentum Clinical Research Taringa

Brisbane, Queensland, Australia

Paratus Clinical(Clinical Trials Institute, Torquay)

Torquay, Victoria, Australia

Chonnam National University Hospital

Gwangju, Donggu, South Korea

The Catholic University of Korea, Eunpyeong St. Mary's Hospital

Seoul, Eunpyeong-gu, South Korea

Wonju Severance Christian Hospital

Wŏnju, Gangwon-do, South Korea

Inha University Hospital

Incheon, Jung-gu, South Korea

Hallym University Sacred Heart Hospital Gangnam

Seoul, Seoul, South Korea

Kaohsiung Medical University Hospital

Kaohsiung City, Kaohsiung, Taiwan

Taichung Veterans General Hospital

Taichung, Taichung, Taiwan

Taipei Medical University Hospital

Taipei, Taipei, Taiwan

Taoyuan General Hospital

Taoyuan, Taoyuan, Taiwan

Chang Gung Memorial Hospital, Linkou Branch

Taoyuan, Taoyuan, Taiwan

Research Institute of Virology

Tashkent, Tashkent, Uzbekistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07157007

Related Trials

Patient-Centered Practical Vaccine Talk For Busy Clinicians

NCT076517611 location

Serological and PCR Testing for COVID-19

NCT044040621 location

Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

NCT052421591 location

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

NCT076551801 location

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT075363086 locations